Biotech Investment Research
1011 companies · 3036 drug programs · 5129 trials · 46 countries
Companies
1,011
Public
646
Drugs
3,036
Trials
5,129
Active
2,062
Catalysts
4,575
Targets
70
Indications
100
Countries
46
Pipeline by Phase
404Pre
377P1
376P1/2
370P2
387P2/3
387P3
375NDA
360App
By Market Cap
Micro190
Small194
Mid174
Large88
Private365
Top Countries
US516
CN82
GB43
KR39
IN34
CA31
JP29
DE25
Upcoming Catalysts
| Date | When | Company | Drug | Type | Phase | Indication |
|---|---|---|---|---|---|---|
| 2026-03-16 | today | 207-2754 | Ph2 Data | Phase 1/2 | ||
| 2026-03-16 | today | 460-4909 | Interim | Preclinical | ||
| 2026-03-16 | today | Sovabrutinib | Ph3 Readout | NDA/BLA | ||
| 2026-03-16 | today | RIC-5834 | Ph3 Readout | Phase 2/3 | ||
| 2026-03-16 | today | SEV-IIT-824 | Ph2 Data | Phase 2 | ||
| 2026-03-16 | today | PBL-710 | AdCom | Approved | ||
| 2026-03-16 | today | CGE-1983 | PDUFA | Phase 2/3 | ||
| 2026-03-17 | tomorrow | GSK-4334 | Interim | Preclinical | ||
| 2026-03-17 | tomorrow | GIL-2037 | Ph3 Readout | Approved | ||
| 2026-03-17 | tomorrow | VRT-1891 | Interim | Phase 1 | ||
| 2026-03-17 | tomorrow | RXR-1394 | Ph3 Readout | Phase 3 | ||
| 2026-03-18 | 2d away | Gelisacituzumab | Ph2 Data | Phase 2 | ||
| 2026-03-18 | 2d away | Miriratamab | Ph3 Readout | Phase 2/3 | ||
| 2026-03-18 | 2d away | DIV-3233 | Ph3 Readout | Phase 2/3 | ||
| 2026-03-19 | 3d away | Elrarapivir | Interim | Phase 1 | ||
| 2026-03-19 | 3d away | Suramavacamten | Interim | Phase 1 | ||
| 2026-03-19 | 3d away | Surasacituzumab | Ph3 Readout | Phase 3 | ||
| 2026-03-19 | 3d away | TEM-8322 | PDUFA | Preclinical | ||
| 2026-03-20 | 4d away | ILM-4317 | Ph3 Readout | NDA/BLA | ||
| 2026-03-20 | 4d away | Olpafutibatinib | Ph3 Readout | Phase 3 | ||
| 2026-03-20 | 4d away | TES-1600 | Ph2 Data | Phase 1/2 | ||
| 2026-03-20 | 4d away | DAN-IIT-515 | Enrollment Complete | Preclinical | ||
| 2026-03-21 | 5d away | BII-5240 | Ph3 Readout | Phase 2/3 | ||
| 2026-03-21 | 5d away | MD-IIT-494 | Interim | Phase 1 | ||
| 2026-03-21 | 5d away | Cevimavacamten | Ph2 Data | Phase 1/2 |
Near FDA Approval
| Company | Tier | Cap | Lead Program | Phase | Drugs |
|---|---|---|---|---|---|
| Eli Lilly | Large | $750B | Phase 3 | 14 | |
| Novo Nordisk | Large | $550B | Phase 3 | 14 | |
| Johnson & Johnson | Large | $380B | NDA/BLA | 14 | |
| AbbVie | Large | $310B | Phase 3 | 14 | |
| Merck & Co | Large | $290B | NDA/BLA | 14 | |
| AstraZeneca | Large | $230B | Phase 3 | 14 | |
| Roche | Large | $220B | Phase 3 | 14 | |
| Novartis | Large | $210B | Phase 3 | 14 |
Target Landscape
PD-1 (39)PD-L1 (44)CDK4/6 (49)KRASG12C (52)BTK (30)JAK1 (35)JAK2 (52)GLP-1R (53)VEGF (42)HER2 (42)EGFR (33)BCL-2 (38)PI3Kα (45)PARP (49)CD19 (41)IL-17A (50)TNFα (41)PCSK9 (41)SGLT2 (39)ALK (25)FGFR (39)FLT3 (39)RET (46)MET (43)TROP-2 (44)Cl18.2 (35)TIM-3 (42)LAG-3 (37)TIGIT (38)TYK2 (44)IL-23 (42)FcRn (51)C5 (60)SMN2 (39)CFTR (51)GIP-R (45)CGRP (46)CD3 (36)Aβ (42)Tau (45)KRASG12D (42)Menin (39)WEE1 (37)CD20 (43)DLL3 (42)